Increased Right Ventricular Assist Device (RVAD) Utilization in Patients with HeartMate 3 Left Ventricular Assist Device (LVAD) in the Post-Approval Era

D. Marshall, E. DeFilippis,L. Truby, A. Malick,C. Butler,J. Griffin,K. Clerkin,J. Fried,J. Raikhelkar, M. Yuzefpolskaya,P. Colombo,G. Sayer,K. Takeda,H. Takayama,Y. Naka,M. Farr,N. Uriel,V.K. Topkara

JOURNAL OF HEART AND LUNG TRANSPLANTATION（2020）

引用 1|浏览73

暂无评分

摘要

Level of sickness at the time of device implantation as well as need for RVAD utilization increased substantially in HM3 patients following the FDA approval. However, the change in practice did not adversely affect post-LVAD morbidity or mortality.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要